Shire Pharmaceuticals Group Plc

Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012

Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012.

Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows:

        UK dial in:    0800-077-8492 or 0844-335-0351
        US dial in:    1-866-8048688 or 1-718-3541175
        International
        dial in:       +44-844-335-0351
        Global Access
        Numbers:    http://www.btconferencing.com/globalaccess/?bid=54_attended
        Password/Conf
        ID:            338 270
        Live Webcast:  http://www.shire.com/shireplc/en/investors 

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

        Investor Relations Souheil Salah ssalah@shire.com+44-1256-894-160
                           Erin K. Kelly erikelly@shire.com  +1-781-482-9541 

 


Weitere Meldungen: Shire Pharmaceuticals Group Plc

Das könnte Sie auch interessieren: